NASOVAC-S, Influenza Vaccine, freeze dried is a live trivalent vaccine for administration by intranasal spray. NASOVAC-S contains three vaccine virus strains of A/H1N1, A/H3N2 and Type B influenza virus cultivated on embryonated hen eggs. The three strains are antigenically similar to the strains recommended by the World Health Organization (W.H.O.) for 2014. NASOVAC-S is indicated in individuals above 2 years of age for the active immunization for the prevention of influenza disease caused by two influenza A subtype viruses and one influenza Type B virus which are expected to circulate in the 2014 season.
Each freeze-dried vaccine vial is reconstituted using the entire contents of sterile water for inhalation that is supplied along with the vaccine, using the supplied syringe and plastic draw up needle.
A dose of 0.5 ml is administered as 0.25 ml per nostril using a 1.0 ml syringe and a spray device. The spray device creates a fine spray that primarily deposits the vaccine in the nose and nasopharynx. A single intranasal dose of 0.5 ml ( is recommended for people above 2 years of age.The vaccine complies with the W.H.O. recommendations.
Serum Institute of India Ltd.
NASOVAC-S is contraindicated in individuals with a history of hypersensitivity, especially anaphylactic reactions to eggs, egg proteins, gelatin, or Lactalbumin or with other vaccine components. NASOVAC-S is contraindicated in children and adolescents (2-17 years of age) receiving aspirin therapy or aspirin-containing therapy, because of the association of Reye's syndrome with aspirin and wild-type influenza infection.